Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals. 

Biotechnology

Health Care

Life Sciences

Therapeutics

Radionetics Oncology

Paul Grayson

Linda McLaughlin

Janine Case

Kristrun Thordis Stardal

Brett Ewald

Yunfei Zhu

Istvan Molnar

The Leadership Team at Radionetics Oncology is responsible for setting the strategic direction of the company, overseeing the development and advancement of its innovative radiotherapeutics pipeline, and ensuring operational excellence. Comprised of key executives from various disciplines, including operations, biology, research, and medical affairs, this team collaborates to drive the execution of clinical and research initiatives, foster partnerships, and navigate regulatory pathways to bring cutting-edge cancer treatments to market.

Leadership Team

Research and Development

Human Resources and Administration

Leadership Team

About

Team members

Other teams at Radionetics Oncology

Research and Development

Human Resources and Administration